People in the News: Arthur Levin, Dennis Ausiello | GenomeWeb

Miragen Therapeutics has named Arthur Levin as its new executive vice president of research and development.

In this role, Levin will be responsible for advancing the company's drug candidates into clinical development and for leading drug-discovery research efforts, according to Miragen.

Levin previously served as chief development officer and president of Santaris Pharma's US operations. Before that, he was senior vice president of development at Isis Pharmaceuticals.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.